AIM – A Decade of Achievement€¦ · Hutchison China Meditech and Boohoo all have market...

12
Disclaimer: Attention of readers is drawn to important disclaimers printed at the end of this document AIM – A Decade of Achievement By Nigel Hawkins, Hardman & Co Analyst AIM, which was founded in 1995, now hosts 959 stocks, currently worth over £100 billion. Since its founding, over £100 billion has been raised by AIM-quoted stocks – with 2006 and 2007 being its best years. The AIM Index has risen by 31% over the last year and by over 60% during the last five years. Impressive. AIM now hosts eleven companies with valuations of over £1 billion each, led by top on-line clothing retailer ASOS, currently worth c£5 billion. Liquidity on AIM has improved remarkably in recent years – Click here to read Keith Hiscock’s article: Liquidity - little understood, even before MIFID II. November 2017

Transcript of AIM – A Decade of Achievement€¦ · Hutchison China Meditech and Boohoo all have market...

Page 1: AIM – A Decade of Achievement€¦ · Hutchison China Meditech and Boohoo all have market capitalisations of c £2.5bn – all are young companies. Although the future for AIM looks

Disclaimer: Attention of readers is drawn to important disclaimers printed at the end of this document

AIM – A Decade of Achievement By Nigel Hawkins, Hardman & Co Analyst

► AIM, which was founded in 1995, now hosts 959 stocks, currently worth over £100 billion.

► Since its founding, over £100 billion has been raised by AIM-quoted stocks – with 2006 and 2007 being its best years.

► The AIM Index has risen by 31% over the last year and by over 60% during the last five years. Impressive.

► AIM now hosts eleven companies with valuations of over £1 billion each, led by top on-line clothing retailer ASOS, currently worth c£5 billion.

► Liquidity on AIM has improved remarkably in recent years – Click here to read Keith Hiscock’s article: Liquidity - little understood, even before MIFID II.

November 2017

Page 2: AIM – A Decade of Achievement€¦ · Hutchison China Meditech and Boohoo all have market capitalisations of c £2.5bn – all are young companies. Although the future for AIM looks

AIM – A Decade of Achievement

November 2017 2

AIM – A Decade of Achievement

Executive Summary ► AIM, which was set up in 1995, continues to prosper despite serious concerns

about its future following the financial crisis of 2008/09. In short, it is now in rude health.

► Currently, 959 stocks are quoted on AIM, 43% below the record 1,694 that were quoted in 2007. As the increase in total AIM capitalisation suggests – the 2007 figure was £97.6bn v £100.2bn currently - the quality - perceived or otherwise - of AIM-quoted stocks has risen.

► The comparisons with 1995 underline how AIM has expanded; there were just 121 stocks then quoted, worth a modest £2.4bn. Importantly, too, AIM has been disproportionately skewed towards the new economy, with a substantial number of internet, technology and biotech stocks.

► Since 1995, AIM has raised c£104bn, with 2006 and 2007 being its most successful years – raising around £16bn in each of those years - compared with our estimated 2017 figure of £5.5bn. Interestingly, the majority of the money raised derives from further issues of existing AIM stocks rather than from those undertaking an IPO.

► AIM currently hosts 11 stocks with market capitalisations of over £1bn. The largest is on-line fashion business, ASOS, worth c£5bn. Fevertree Drinks, Hutchison China Meditech and Boohoo all have market capitalisations of c£2.5bn – all are young companies.

► Although the future for AIM looks bright, it could be disrupted by a weak economy, higher interest rates, tighter regulation, a less-friendly tax regime or even AIM-related shortcomings.

The 2008/09 Financial Crisis AIM is now 22 years old and is enjoying a rich vein of form as stock markets reach record levels. Indeed, the AIM-100 Index is now 5,184, compared with 3,950 one year ago and 3,200 at the end of October 2012. When compared with 2012, the AIM-100 Index has risen by over 60%.

The Graph below shows the resilience of AIM’s stock market performance over the last five years, especially considering all the downside factors which it has had to confront.

Rich vein…

AIM’s resilience…

Page 3: AIM – A Decade of Achievement€¦ · Hutchison China Meditech and Boohoo all have market capitalisations of c £2.5bn – all are young companies. Although the future for AIM looks

AIM – A Decade of Achievement

November 2017 3

5- year AIM-100

Source: Eikon Thomson Reuters

It should also be recognised that, back in 2008/09, when the financial crisis was at its height, there were real doubts about AIM’s ability to adjust successfully to a far less up-beat economic scenario. After all, the Government had just sunk £45.5bn of taxpayers’ money into Royal Bank of Scotland, with a further c£20 billion into the ill-fated Lloyds/HBOS merger.

AIM’s subsequent success has proven that it is not simply a bull-market phenomenon - although its market value peak (including all AIM stocks) was in 2007 – it fell sharply as the financial crisis took hold. Once full-year figures are available for 2017, it seems virtually certain that the current year will exceed the previous 2007 peak not just in nominal terms but also in real terms.

Of course, AIM has had its share of troubles and critics, especially on the issue of insufficient due diligence. As the peak membership figures for 2006 and 2007 imply, a large number of companies have disappeared subsequently, many due to insolvency.

With so many companies quoted - 959 at September 2017 - it is hardly surprising that AIM has faced robust criticism. The long-running controversy over the insurance claims business, Quindell - now re-named Waterstone – raised several fundamental questions about AIM and especially its oversight of complex companies, of which Quindell was undoubtedly one.

Daily .FTAIM1 26/10/2012 - 25/10/2017 (LON)Line, .FTAIM1, Trade Price(Last), 25/10/2017, 5,201.76, +13.59, (+0.26%) Price

GBP

Auto3,000

3,200

3,400

3,600

3,800

4,000

4,200

4,400

4,600

4,800

5,000

5,2005,201.76

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q42013 2014 2015 2016 2017

No bull market phenomenon…

High attrition rate…

Page 4: AIM – A Decade of Achievement€¦ · Hutchison China Meditech and Boohoo all have market capitalisations of c £2.5bn – all are young companies. Although the future for AIM looks

AIM – A Decade of Achievement

November 2017 4

Background AIM’s history dates back to the early 1990s and the decision to establish a new market whose listing requirements were considerably less onerous than those required for a full market quote. To a certain extent, it reflected an era of rapid change as new technology companies, some internet-based, emerged.

Figure 1 below shows how AIM has developed since 1995. By any measure, its expansion has been mightily impressive, especially post the financial crisis of 2008/09. In fact, the first nine months of this year have seen a market value for AIM stocks exceeding £100bn for the first time. Once a full-year figure is available, 2017 will be – short of a major market correction – a record year in terms of AIM market capitalisation.

Figure 1 – AIM Historic Data Year Companies Market Value

(£m) New Money Raised

(£m) Further Money Raised

(£m) Total Money Raised

(£m) 19/06/1995 10 82 1995 121 2,382 71 25 97 1996 252 5,299 522 297 819 1997 308 5,665 344 350 694 1998 312 4,438 268 318 585 1999 347 13,469 334 600 934 2000 524 14,935 1,754 1,338 3,092 2001 629 11,607 593 535 1,128 2002 704 10,252 490 486 976 2003 754 18,359 1,095 1,000 2,095 2004 1,021 31,753 2,776 1,880 4,655 2005 1,399 56,619 6,461 2,481 8,942 2006 1,634 90,666 9,944 5,734 15,678 2007 1,694 97,561 6,581 9,602 16,183 2008 1,550 37,732 1,108 3,215 4,322 2009 1,293 56,632 740 4,831 5,602 2010 1,195 79,419 1,201 5,649 6,850 2011 1,143 62,213 614 3,681 4,295 2012 1,096 61,748 712 2,451 3,163 2013 1,087 75,929 1,191 2,716 3,907 2014 1,104 71,414 2,604 3,122 5,727 2015 1,044 73,077 1,240 4,216 5,456 2016 982 80,814 1,104 3,662 4,766 2017 (YTD) 959 100,238 1,225 2,766 3,990 Total 42,972 60,985 103,957

Source: London Stock Exchange

The comparison with the 2004 data is interesting in that the number of companies then quoted is slightly above the current figure yet AIM’s total market capitalisation at that time was just a third of the existing figure.

In short, this suggests that the overall quality of AIM stocks is rising. It is the case, though, that the ‘Big 11’ £1 billion market capitalisation stocks, and especially ASOS, seriously skew the comparison.

£100bn valuation threshold

reached in 2017…

Big 11 skew figures…

Page 5: AIM – A Decade of Achievement€¦ · Hutchison China Meditech and Boohoo all have market capitalisations of c £2.5bn – all are young companies. Although the future for AIM looks

AIM – A Decade of Achievement

November 2017 5

Although the amount of money now being raised is well below the totals for 2006 and 2007, the fact remains that, for the 2017 full-year, an estimated £5.5bn of additional funding is expected to have been secured, mostly from existing AIM-quoted companies rather than from new market entrants.

Liquidity There have been long-standing concerns, especially from those considering an AIM flotation, that AIM-quoted stocks lack liquidity, particularly in respect of the smaller AIM stocks where trading levels are low. Significantly, however, trading volumes on AIM continue to rise, as comparisons with 2007 – the year before the financial crisis – indicate. Significantly, trading volumes in 2017 are expected to be over five times those of a decade ago. Figure 2 tracks the trading trends since 1995: Executive summary

Figure 2 – Trading Data Year Turnover Value (£m) Number of Trades Volume of Trades (m) 1995 270 29,099 544 1996 1,944 187,975 5,529 1997 2,415 217,426 6,443 1998 1,938 215,555 6,174 1999 5,178 829,480 19,862 2000 13,010 1,970,321 35,770 2001 4,583 703,400 26,862 2002 3,154 450,215 25,028 2003 5,859 819,024 56,054 2004 15,335 1,635,785 90,876 2005 37,863 2,120,375 95,850 2006 56,608 3,449,652 129, 923 2007 72,367 4,156,569 143,703 2008 41,775 3,854,643 118,952 2009 27,987 3,762,160 164,073 2010 40,504 5,277,856 197,273 2011 47,783 7,312,198 273,773 2012 48,327 7,154,323 338,616 2013 39,597 6,425,265 490,073 2014 56,544 8,714,460 582,398 2015 41,779 7,476,748 675,361 2016 43,540 8,087,668 693,168 2017 (YTD) 50,028 8,541,625 660,892 Total 658,390 83,391,732 4,837,200

Source: London Stock Exchange

In fact, the issue of AIM liquidity has been carefully analysed by Hardman in recent months.

Indeed, a major analytical insight into AIM liquidity – ‘Liquidity – little understood, even before MiFID II’ - was recently undertaken by Hardman’s Chief Executive, Keith Hiscock. It also addressed the complex research ramifications of MiFID II, whose long-delayed implementation is now due in January 2018.

Hard copies of this Report are available from Hardman; the text is reproduced on the Hardman web-site:

http://hardmanandco.com/docs/default-source/newsletters/hardman-co-article---liquidity-little-understood-even-before-mifid-ii---october-2017.pdf

Estimated £5.5bn of new

funding for 2017…

Trading volumes soar…

Hardman’s AIM liquidity analysis…

Page 6: AIM – A Decade of Achievement€¦ · Hutchison China Meditech and Boohoo all have market capitalisations of c £2.5bn – all are young companies. Although the future for AIM looks

AIM – A Decade of Achievement

November 2017 6

Company Distribution on AIM In assessing recent trends on AIM, it is salutary to consider how market capitalisation is split between its members. Figure 3 below indicates that almost 90% of the total value of AIM stocks is accounted for by companies with a market capitalisation of over £50m.

Figure 3 – Company Size on AIM Value Range (£m) Number of Companies % Equity Value (£m) % Over 1,000 11 1.1 22,673 22.6 500-1,000 33 3.4 22,105 22.1 250-500 50 5.2 16,535 16.5 100-250 131 13.7 20,168 20.1 50-100 120 12.5 8,663 8.6 25-50 168 17.5 6,037 6.0 10-25 175 18.2 2,843 2.8 5-10 99 10.3 759 0.8 2-5 113 11.8 378 0.4 0-2 59 6.2 78 0.1 Totals 959 100 100,238 100

Source: London Stock Exchange

In terms of the number of companies quoted on AIM, most are capitalised within the £10m and £250m level – essentially the AIM sweet spot; this is demonstrated by the bar chart reproduced below.

Distribution of AIM Companies by Equity Market Value

Source: London Stock Exchange

It is also significant that just 44 companies - each worth over £500m each - account for almost half of AIM’s total market value. ASOS, with its c£5bn capitalisation, has a particularly distorting effect on these figures.

59

113 99

175 168

120 131

50 33

11

0

20

40

60

80

100

120

140

160

180

200

90% of AIM value in £50m+

stocks…

AIM’s £10m-£250m sweet

spot…

Page 7: AIM – A Decade of Achievement€¦ · Hutchison China Meditech and Boohoo all have market capitalisations of c £2.5bn – all are young companies. Although the future for AIM looks

AIM – A Decade of Achievement

November 2017 7

New v Further Issues Whilst many market commentaries tend to focus on stocks joining AIM, the fact remains that most of the funds raised on AIM are those that accrue from further issues: the new issue component is more modest.

In fact, AIM’s strength lies particularly in facilitating the raising of additional funds by existing AIM members - this aspect of AIM is underplayed in the financial press and elsewhere. As recent data indicates, this process has seen £2.8bn of further funds being raised in the first nine months of 2017 alone.

Figure 4 provides a breakdown of how this money was generated over this period from a series of further issues. Most dominant are the funds raised though options and warrants.

Figure 4 – Fund-raising Data Month Total

(£m) Cash Placing

(£m) Options and

Warrants (£m) Vendor

(£m) Further Issue

(£m) Others

(£m) Funds Raised

(£m) January 136 25 57 13 16 25 161 February 195 42 84 21 14 34 167 March 199 53 83 18 17 28 320 April 200 30 95 20 21 34 257 May 200 53 79 16 24 28 317 June 209 45 95 18 16 35 352 July 170 34 71 13 26 26 630 August 153 30 64 18 14 27 361 September 131 21 56 14 20 20 201 Total 1,593 333 684 151 168 257 2,766

Source: London Stock Exchange

In terms of sector split, Figure 5 provides a break-down of how new and further money has been raised on AIM during the first nine months of 2017.

Figure 5 – Sector Analysis Sector New Issues New Money

(£m) Further Issues Further Money

(£m) Oil/Gas 9 81 191 485 Basic Materials 4 13 399 247 Industrials 11 350 186 246 Consumer Goods 2 37 38 38 Health Care 3 50 189 457 Consumer Services 4 77 146 134 Telecoms 1 40 20 210 Utilities 0 0 17 5 Financials 12 523 179 386 Technology 6 53 228 558 Total Equities 52 1,225 1,593 2,766

Source: London Stock Exchange

Whilst the above data covers just the last nine months, it does show several key sectors raising money, with the exception of the utilities sector, which has very few AIM constituents.

Further issue fund-raising is key

driver…

Options and warrants dominate

further funding…

AIM multi-sector spread…

Page 8: AIM – A Decade of Achievement€¦ · Hutchison China Meditech and Boohoo all have market capitalisations of c £2.5bn – all are young companies. Although the future for AIM looks

AIM – A Decade of Achievement

November 2017 8

AIM’s Stars - The ‘Big 11’ One of the salient features of the AIM story since 1995 is how a few companies have grown very quickly – and aggressively.

To be sure, there is no comparison with the Vodafone story, whereby the former Racal subsidiary – within a generation of its founding – had become, by 1999, the fourth largest company in global history after Microsoft, Cisco and General Electric,

Nonetheless, there are currently 11 companies quoted on AIM, with a market capitalisation of over £1 billion each. Most of them simply did not exist in the 20th century; indeed, several, such as Boohoo, Clinigen and Purplebricks are less than a decade old.

Reproduced below are very brief potted profiles of AIM’s ‘Big 11’ and their latest market capitalisations:

ASOS – Market Cap. £5.0bn. On-line clothing business, ASOS, was launched – despite almost universal misgivings about the financial outlook for on-line clothes sales - in 2002; it now has c13.4m active customers. In terms of age, ASOS targets the 20 something clothing market;

Fevertree Drinks – Market Cap. £2.5bn. Based on a 17th century anti-malaria protection derived from the eponymous tree, Fevertree produced its first Indian tonic water in 2005; its thriving business has been boosted by the recent popularity of gin;

Hutchison China Meditech – Market Cap. £2.4bn. With a pipe-line of novel oral drug candidates, notwithstanding the sale of prescription drugs and consumer health products in China, Hutchison China Meditech has seen increasing investor interest – CK Hutchison retains a majority stake;

Boohoo.com – Market Cap. £2.4bn. Like ASOS, Boohoo is also a major player in the on-line youth clothing market. It was founded in Manchester in 2008 and had 5.2m active customers as at February 2017;

Burford Capital* – Market Cap. £2.2bn. A major provider of finance to the legal market, Burford participates in a market where there are demonstrably unequal resources in litigation outcomes; it was founded in 2009;

Abcam – Market Cap. £2.1bn. Having originally been established to buy anti-bodies via the internet, the Cambridge-based Abcam has become a global player in the supply of life science tools. Its current AIM valuation is c10x its 2016/17 revenues;

No Vodafone…

Page 9: AIM – A Decade of Achievement€¦ · Hutchison China Meditech and Boohoo all have market capitalisations of c £2.5bn – all are young companies. Although the future for AIM looks

AIM – A Decade of Achievement

November 2017 9

Phoenix Global Resources – Market Cap. £1.5bn. Oil and gas, primarily in Argentina where it owns substantial resources, are the core businesses of Phoenix Global Resources. It joined AIM in 2007 and has evolved – as its name suggests – via various corporate deals in South America;

Breedon – Market Cap. £1.2bn. Originally Enstone, the East Midlands-based Breedon is the largest independent construction group in the UK. It was founded in 2008 and owns key building assets including the UK’s largest cement plant;

Clinigen – Market Cap. £1.2bn. In 2010, three health businesses were merged to form Clinigen, which specialises in being a major procurer of medicines from a wide range of sources;

Purplebricks* – Market Cap. £1.1bn. Set up as recently as 2012 in the Midlands, Purplebricks has firmly established itself as a major disruptor in the estate agency market, where it is the leading on-line 24/7 agent;

Plus500 – Market Cap. £1.0bn. Established in 2008, Plus500’s expertise lies in trading Contracts for Differences (CfDs), which have been widely used in the electricity supply industry since privatisation. Plus500 has Israeli origins and undertook an IPO on AIM in 2013.

N.B. Please note that companies marked with an asterisk are Hardman clients.

The Future of AIM

Although AIM has prospered over the last 22 years, there is no guarantee that its expansion will continue. A major economic down-turn on the back of rising global interest rates – a favoured scenario by market bears - could test AIM’s resilience.

Nonetheless, given how AIM surmounted the financial crisis in 2008/09, it remains well-placed to expand and to enable more new and further funds to be raised by its membership.

In addressing AIM’s prospects for the future, we believe there are several criteria that need to be in place:

► Continuing good performances from the leading companies quoted on AIM and fewer bad news stories, of which the former Quindell controversy stands out;

► An ongoing robust economic performance despite all the uncertainties posed by Brexit and the likelihood of higher interest rates;

► A tax regime that continues to treat AIM stocks favourably – and underpins the prices of some AIM-quoted stocks;

► The ability of AIM to generate genuine liquidity, especially at the lower end of the market;

► The avoidance of excessive regulatory involvement, which could be triggered by further AIM-related scandals.

Downside risks for AIM…

Page 10: AIM – A Decade of Achievement€¦ · Hutchison China Meditech and Boohoo all have market capitalisations of c £2.5bn – all are young companies. Although the future for AIM looks

AIM – A Decade of Achievement

November 2017 10

Conclusion The overall conclusion is that AIM is currently in rude health – it is still the fastest-growing stock market in the world. It acts as a host to almost 1,000 companies and, by the 2017 full-year, should have assisted in raising c£5.5bn of new and further capital – an impressive figure.

But if the economy turns south – a far from improbable scenario – AIM may look back on 2017 as a year of plenty.

About the author

Nigel Hawkins undertakes analysis of the Utilities sector at Hardman, along with working on some special projects.

He has been an investment analyst since 1989, focussing on the UK/EU privatised water and electricity sectors as well as the gas and telecom companies. He has worked at Hoare Govett, Yamaichi and Williams de Broe.

Before joining the City, he worked as Political Correspondence Secretary to Lady Thatcher at 10 Downing Street between 1984 and 1987. Prior to that, he qualified as an Associate of the Institute of Chartered Secretaries and Administrators (AICS) and graduated in Law, Economics and Politics from Buckingham University.

In rude health currently…

But the worm may turn…

Page 11: AIM – A Decade of Achievement€¦ · Hutchison China Meditech and Boohoo all have market capitalisations of c £2.5bn – all are young companies. Although the future for AIM looks

AIM – A Decade of Achievement

November 2017 11

Disclaimer Hardman & Co provides professional independent research services. Whilst every reasonable effort has been made to ensure that the information in the research is correct, this cannot be guaranteed.

The research reflects the objective views of the analysts named on the front page. However, the companies or funds covered in this research may pay us a fee, commission or other remuneration in order for this research to be made available. A full list of companies or funds that have paid us for coverage within the past 12 months can be viewed at http://www.hardmanandco.com/

Hardman & Co has a personal dealing policy which debars staff and consultants from dealing in shares, bonds or other related instruments of companies which pay Hardman for any services, including research. They may be allowed to hold such securities if they were owned prior to joining Hardman or if they were held before the company appointed Hardman. In such cases sales will only be allowed in limited circumstances, generally in the two weeks following publication of figures.

Hardman & Co does not buy or sell shares, either for its own account or for other parties and neither does it undertake investment business. We may provide investment banking services to corporate clients.

Hardman & Co does not make recommendations. Accordingly, we do not publish records of our past recommendations. Where a Fair Value price is given in a research note this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities/companies but has no scheduled commitment and may cease to follow these securities/companies without notice.

Nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell securities by us.

This information is not tailored to your individual situation and the investment(s) covered may not be suitable for you. You should not make any investment decision without consulting a fully qualified financial adviser.

This report may not be reproduced in whole or in part without prior permission from Hardman &Co.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority (FCA) under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259. However, the information in this research report is not FCA regulated because it does not constitute investment advice (as defined in the Financial Services and Markets Act 2000) and is provided for general information only.

Hardman & Co Research Limited (trading as Hardman & Co) 35 New Broad Street London EC2M 1NH T +44 (0) 207 194 7622 Follow us on Twitter @HardmanandCo (Disclaimer Version 2 – Effective from May 2017)

Page 12: AIM – A Decade of Achievement€¦ · Hutchison China Meditech and Boohoo all have market capitalisations of c £2.5bn – all are young companies. Although the future for AIM looks

AIM – A Decade of Achievement

November 2017 12

Hardman Team Management Team +44 (0)20 7194 7622 John Holmes [email protected] +44 (0)207 194 7629 Chairman Keith Hiscock [email protected] +44 (0)207 194 7630 CEO Marketing / Investor Engagement +44 (0)20 7194 7622 Richard Angus [email protected] +44 (0)207 194 7635 Max Davey [email protected] +44 (0)207 194 7622 Antony Gifford [email protected] +44 (0)207 194 7622 Vilma Pabilionyte [email protected] +44 (0)207 194 7637 Gavin Laidlaw [email protected] +44 (0)207 194 7627 Ann Hall [email protected] +44 (0)207 194 7622 Analysts +44 (0)20 7194 7622 Agriculture Bonds Doug Hawkins [email protected] Brian Moretta [email protected] Yingheng Chen [email protected] Mark Thomas [email protected] Thomas Wigglesworth [email protected] Building & Construction Consumer & Leisure Tony Williams [email protected] Mike Foster [email protected] Mike Foster [email protected] Steve Clapham [email protected] Jason Streets [email protected] Financials Life Sciences Brian Moretta [email protected] Martin Hall [email protected] Mark Thomas [email protected] Gregoire Pave [email protected] Dorothea Hill [email protected] Media Mining Derek Terrington [email protected] Paul Singer [email protected] Oil & Gas Property Angus McPhail [email protected] Mike Foster [email protected] Services Special Situations Mike Foster [email protected] Steve Clapham [email protected] Paul Singer [email protected] Tax Enhanced Services Utilities Brian Moretta [email protected] Nigel Hawkins [email protected] Chris Magennis [email protected]

Hardman & Co 35 New Broad Street London EC2M 1NH Tel: +44(0)20 7194 7622 www.hardmanandco.com